close
References
  1. US White House Office of National Aids Policy. National HIV/AIDS strategy for the United States: updated to 2020. Washington, DC: US Department of Health & Human Services; 2015. www.aids.gov/federal-resources/national-hiv-aids-strategy/nhas-update.pdf. Accessed September 25, 2015.
  2. Centers for Disease Control and Prevention. CDC fact sheet. New HIV infections in the United States. http://www.cdc.gov/nchhstp/newsroom/docs/2012/hiv-infections-2007-2010.pdf. Accessed August 13, 2015.
  3. Centers for Disease Control and Prevention. Today’s HIV/AIDS epidemic. www.cdc.gov/nchhstp/newsroom/docs/factsheets/todaysepidemic-508.pdf. Accessed September 25, 2015.
  4. Hall HI, An Q, Tang T, et al. Prevalence of diagnosed and undiagnosed HIV infection - United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2015;64(24):657-662.
  5. Centers for Disease Control and Prevention. HIV among transgender people in the United States. www.cdc.gov/hiv/pdf/risk_transgender.pdf. Accessed August 25, 2015.
  6. Centers for Disease Control and Prevention. HIV surveillance report, 2013; vol. 25. www.cdc.gov/hiv/library/reports/surveillance/. Accessed August 17, 2015.
  7. Prejean J, Song R, Hernandez A, et al; HIV Incidence Surveillance Group. Estimated HIV incidence in the United States, 2006-2009. PLoS One. 2011;6(8):e17502.
  8. Indiana State Department of Health. Indiana State Department of Health investigates additional HIV cases tied to southeastern Indiana outbreak. www.in.gov/isdh/files/August_28_ISDH__Investigates_Additional_HIV_Cases_Tied_To_Southeastern_Indiana_Outbreak.pdf. Accessed September 25, 2015.
  9. Conrad C, Bradley HM, Broz D, et al. Community outbreak of HIV infection linked to injection drug use of oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64:443-444.
  10. Skarbinski J, Rosenberg E, Paz-Bailey G, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175:588-596.
  11. Rotheram-Borus MJ, Swendeman D, Chovnick G. The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol. 2009;5:143-167.
  12. Alcorn K; aids 2013 Science and Technology Working Group. HIV/AIDS technologies. A review of progress to date and current prospects. 2008. http://www.path.org/publications/files/aids2031_landscape_analysis.pdf. Accessed October 15, 2015.
  13. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group.Lancet. 1997;
    349(9069):1868-1873.
  14. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998;280(1):61-66.
  15. Centers for Disease Control and Prevention. PEP. www.cdc.gov/hiv/basics/pep.html. Accessed September 25, 2015.
  16. Centers for Disease Control and Prevention. Prevention benefits of HIV treatment. www.cdc.gov/hiv/prevention/research/tap/. Accessed September 25, 2015.
  17. Cáceres CF, Koechlin F, Goicochea P, et al. The promises and challenges of pre-exposure prophylaxis as part of the emerging paradigm of combination HIV prevention. J Int AIDS Soc. 2015;18(suppl 3):19949.
  18. Global Forum on MSM & HIV. Serosorting and strategic positioning. www.msmgf.org/files/msmgf/documents/TechBulletins/EN/Sec5MSMGF_TechBulletins2012.pdf. Accessed September 25, 2015.
  19. Vallabhaneni S, Li X, Vittinghoff E, Donnell D, Pilcher CD, Buchbinder SP. Seroadaptive practices: association with HIV acquisition among HIV-negative men who have sex with men. PLoS One. 2012;7(10):e45718.
  20. Truvada [package insert]. Foster City, CA: Gilead Sciences, Inc. 2013.
  21. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587-2599.
  22. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820-829.
  23. Baeten J, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Conference on Retroviruses and Opportunistic Infections (CROI); February 23-26, 2015; Seattle, WA. Abstract 24.
  24. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015 Sep 9. [Epub ahead of print].
  25. Liu A, Cohen S, Vittinghoff E, et al. Adherence, sexual behavior and HIV/STI incidence among men who have sex with men (MSM) and transgender women (TGW) in the US PrEP demonstration (Demo) project.  Eighth International AIDS Society Conference on HIV Pathogenesis; Vancouver, Canada; 2015.
  26. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015 Sept 1. [Epub ahead of print].
  27. Molina JM, Capitant C, Spire B, et al. On demand PrEP with oral TDF-FTC in MSM: results of the ANRS Ipergay trial.  Conference on Retroviruses and Opportunistic Infections (CROI); February 23-26, 2015; Seattle, WA. Abstract 23LB.
  28. National Institutes of Health. Clinicaltrials.gov. Accessed September 28, 2015.
  29. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-434.
  30. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
  31. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411-422.
  32. Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509-518.
  33. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083-2090.
  34. Holtz TH, Chitwarakorn A, Curlin ME, et al. HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, abstract MOAC0306LB, 2015.
  35. Mannheimer S, Hirsch-Moverman Y, Loguere A, et al. HPTN 067/ADAPT study: a comparison of daily and intermittent pre-exposure prophylaxis (PrEP) dosing for HIV prevention in men who have sex with men and transgender women in New York city. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, abstract MOAC0305LB, 2015.
  36. Bekker LG, Hughes J, Amico R, et al. HPTN 067/ADAPT Cape Town: A comparison of daily and nondaily PrEP dosing in African women. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, poster 978LB, 2015.
  37. Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2015;68(3):337-344.
  38. Carlo Hojilla J, Koester KA, Cohen SE, et al. Sexual Behavior, Risk Compensation, and HIV Prevention Strategies Among Participants in the San Francisco PrEP Demonstration Project: a qualitative analysis of counseling notes. AIDS Behav. 2015 Apr 3. [Epub ahead of print].
  39. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: a clinical practice guideline. www.cdc.gov/hiv/pdf/prepguidelines2014.pdf. Accessed August 25, 2015.
  40. Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States–2014: clinical providers' supplement. www.cdc.gov/hiv/pdf/prepprovidersupplement2014.pdf. Accessed August 25, 2015.
  41. Branson BM, Handsfield HH, Lampe MA, et al; Centers for Disease Control and Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR14):1-17.
  42. Centers for Disease Control and Prevention. Planning and implementing HIV testing and linkage programs in non-clinical settings: a guide for program managers. https://effectiveinterventions.cdc.gov/docs/default-source/public-health-strategies-docs/HIVTestingImplementationGuide_Final.pdf. Accessed September 18, 2015.